Author's response to reviews

Title: Latin American Consensus: Children Born Small for Gestational Age

Authors:

Margaret C S Boguszewski (marabogus@uol.com.br)
Veronica Mericq (vmericq@med.uchile.cl)
Ignacio Bergada (ibergada@cedie.org.ar)
Durval Damiani (durvald@iconet.com.br)
Alicia Belgorosky (abelgo@elsitio.net)
Peter Gunczler (petergunczler@hotmail.com)
Teresa Ortiz (tortizpm@yahoo.com)
Mauricio Llano (mllananomd@cable.net.co)
Horacio M Domene (hdomene@cedie.org.ar)
Raul Calzada-Leon (raulcalzada@yahoo.com)
Armando Blanco (ablancol@prodigy.net.mx)
Margarita Barrientos (marga_barrientos@yahoo.com)
Patricio Procel (patricioprocel@panchonet.net)
Roberto Lanes (lanesroberto@gmail.com)
Orlando Jaramillo (drojaramillo@yahoo.com)

Version: 5 Date: 17 June 2011

Author's response to reviews: see over
June 16, 2011

Dear Ms Neilan:

Re: Latin American Consensus: Children Born Small for Gestational Age

We are delighted that the manuscript has been accepted for publication in BMC Pediatrics.

As per your request, we have addressed the remaining point by Referees 1 & 2 and enclosed our response.

Yours sincerely,

Margaret C S Boguszewski, MD (on behalf of all authors)
1. There is only one point which deserves some attention (page 13):

Laboratory measurements should be performed at regular intervals. Although I think that measuring indices of insulin sensitivity is not valuable for the majority of GH-treated children, measurement of IGF-1 levels is. Please, state that measuring the IGF-1 level once a year is necessary, but preferably this should be done twice a year.

Revised statement (in section Baseline assessment and follow-up during GH treatment):

While it is necessary to measure IGF-1 levels once a year, twice a year is preferred.

2. Quality of written English: Needs some language corrections before being Published

Edited final document and made language corrections where needed.

2nd Reviewer’s report

1. With regards to the competing interests sections our Editor noticed that you mention Pfizer funding in your acknowledgements. This needs to be removed from the acknowledgements section and added into the competing interests section.

Revised statement in Competing Interests section to reflect funding by Pfizer.

2. Author Comment: Background: "Leading experts in pediatrics, endocrinology, and neonatology .." - we were only pediatric endocrinologists.

Revised forth page to read: In Latin America, identification and optimal management of children born SGA is a critical issue. Leading experts in pediatric endocrinology throughout Latin America established working groups in order to discuss key challenges regarding the evaluation and management of children born SGA and ultimately develop a consensus statement.